BioCardia (BCDA) Stock Price

BioCardia Price

NASDAQ·CLOSED
0.90
​
Market closed

Revenue at BioCardia has contracted by 13.2% per year over the past 17 years to 58,000.00 USD. Earnings per share have declined at 69.7% per year over the last 4 years. BioCardia's net margin stands at -13,700.0%, down from -10,347.6% several years earlier.

BioCardia stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioCardia business model & stock analysis

BioCardia, Inc. operates as a clinical-stage regenerative medicine company. The company is headquartered in San Carlos, California and currently employs 20 full-time employees. The firm's therapeutic portfolio consists of the CardiAMP and CardiALLO cell therapies. The firm's lead therapeutic candidate is the CardiAMP Cell Therapy System (CardiAMP) and focuses on the Phase III trial for CardiAMP in ischemic systolic heart failure. The firm's CardiALLO Cell Therapy System (CardiALLO), is an allogeneic off the shelf mesenchymal stem cell product candidate from other donors. The Company’s products also include Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products.

Frequently asked questions about BioCardia

8 analysts currently rate the BioCardia stock: 7 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the BioCardia share trades at 0.80 EUR (0.90 USD).

The BioCardia share (BCDA) is listed on 3 stock exchanges, including: NASDAQ (BCDA), Frankfurt (6JU.F), München (6JU.MU).

The revenue cannot currently be calculated for BioCardia.

The expected profit of BioCardia is -7.53 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of BioCardia is currently -1.28. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BioCardia stock.

The P/S cannot be calculated for BioCardia currently.

The Eulerpool Quality Score for BioCardia is 2/10.

The ISIN of BioCardia is US09060U6064. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of BioCardia is A2PLXH. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of BioCardia is BCDA. The ticker symbol is used to trade BioCardia shares on the stock exchange.

Fair ValueTerminal
0.76 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Nov 13, 1996
ISIN
US09060U6064
Cusip
09060U507
Sedol
BJTN273
Market capitalization
9.52 M USDMicro Cap
52-Week Range
PEG
0.07
P/E ratio
P/Ee 2026
-1.28
P/Ee 2027
-1.57
P/Ee 2028
-2.30
P/Se
—
EV/EBIT
—
P/B Ratio
10.64
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-578.22 %
Last updated Oct 20, 2026, 8:47 AM

BioCardia Ticker

FRANKFURT · 6JU.FMUNICH · 6JU.MUNASDAQ · BCDA

All fundamentals and in-depth analysis of BioCardia

Our stock analysis for BioCardia stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioCardia. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.